Skip to main content
Premium Trial:

Request an Annual Quote

Norman Russell and Al Kolb

Premium

Invitrogen last week said that Norman Russell has joined the company as vice president and general manager of the functional genomics strategic business unit.

In this role, Invitrogen said, Russell will lead the company’s genomics, proteomics, and RNAi product lines. He joins Invitrogen from Aviva Biosciences, where he served as president and CEO. Prior to that, Russell was president and CEO of Lynx Therapeutics. He also served for many years for AstraZeneca, Invitrogen said. Russell holds a PhD in physiology from Glasgow University.


Al Kolb is currently serving as the 2004-2005 president elect for the Society for Biomolecular Screening, the organization announced last week. He will assume the presidency at the society’s 11th Annual Conference and Exhibition to be held Sept. 11-15 in Geneva.

Kolb is a consultant for KeyTechnology Consulting in Madison, Conn. He was one of the founding members of the society, SBS said, and a member of the first board of directors in 1994, and from 1999 through 2000. He has also served as a member of the editorial board of the Journal of Biomolecular Screening since its inception. Kolb holds a PhD in molecular biology from the University of California, Irvine, and completed a postdoctoral fellowship at the Roche Institute for Molecular Biology.

 

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.